iRhythm Holdings (IRTC) is back in focus after a busy presence at the American College of Cardiology 2026 meetings, where it shared new Zio clinical data, AI partnerships, and education and accessibility initiatives.

The share price has retreated in recent months, with a 90 day share price return of a 34.15% decline and a year to date share price return of a 32.56% decline, even as the 1 year total shareholder return sits at 19.61%. This suggests earlier optimism may be cooling despite the fresh ACC.26 data, AI initiatives, and the auditor change to KPMG.

If you are looking beyond cardiac monitoring and AI driven diagnostics, it can be useful to see what else is moving in healthcare related AI. Start your search with 36 healthcare AI stocks

With a recent 34.15% 90 day share price decline, a 1 year total return of 19.61%, and a value score of 4 against growing revenue, is iRhythm now mispriced or are markets already factoring in its future growth?

Most Popular Narrative: 44.1% Undervalued

At a last close of $118.16 against a narrative fair value of $211.43, the current pricing sits well below what the most followed narrative models in, using an 8.09% discount rate to weigh future cash flows.

The growing push towards population health management, preventative care, and value-based reimbursement is aligning directly with Zio's evidence-supported, scalable monitoring platform. This supports both recurring usage and improved payer coverage, which may lead to higher revenues and improved net margins over time.

Curious what has to happen for that fair value to stack up? The narrative leans on faster top line growth, a clear path to profitability, and a valuation multiple usually reserved for high growth leaders. The exact mix of revenue, margin and earnings assumptions behind that conclusion may surprise you.

Result: Fair Value of $211.43 (UNDERVALUED)

However, the DOJ subpoena overhang and ongoing regulatory remediation, along with reliance on a few key channel partners, could quickly weaken the case behind that bullish narrative.

Next Steps

There is clearly a mix of excitement and concern in the story so far, so move quickly, review the full picture, and weigh both sides with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one company, you could miss opportunities that fit your style even better, so widen your search and put more names on your radar.

• Spot potential bargains early by scanning companies flagged as screener containing 24 high quality undiscovered gems that pair solid fundamentals with limited attention from the market.
• Prioritise stability by reviewing 73 resilient stocks with low risk scores that aim to keep overall risk scores on the lower side.
• Strengthen your core holdings by using the solid balance sheet and fundamentals stocks screener (40 results) to find businesses supported by healthier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.